AMENDMENTS TO THE CLAIMS

Please amend the claims to read as follows:

1.-38. (cancelled).

39. (Previously Presented) A compound having the formula:



wherein

A is Cl or CF_3;

C is Cl or CF_3;

D is H or CH_3;

V is F or Cl;

X is a member selected from the group consisting of H, CH_3, COOH, and CO_2CH_3; and

Y is a member selected from the group consisting of H, CO_2H and CO_2CH_3;

or a pharmaceutically acceptable salt thereof.

40. (Previously Presented) The compound of claim 39, wherein V is Cl.

41. (Previously Presented) The compound of claim 39, wherein X and Y are each H.

42. (Previously Presented) The compound of claim 39, wherein A is Cl.

43. (Previously Presented) The compound of claim 39, wherein A is CF_3.

44. (Previously Presented) The compound of claim 39, wherein D is H.

45. (Previously Presented) The compound of claim 39, wherein A is Cl and D is H.

46. (Previously Presented) The compound of claim 39, wherein A is Cl; C is Cl; and V is Cl.

47. (Previously Presented) The compound of claim 39, wherein C is CF_3,

48. (Previously Presented) The compound of claim 39, wherein A is Cl; C is Cl; V is Cl, D is CH_3, and X and Y are each H.

49. (Previously Presented) The compound of claim 39, wherein A is Cl; C is Cl; V is Cl, D is H, and X and Y are each H.

50. (Previously Presented) A composition comprising a pharmaceutically acceptable carrier or excipient and a compound having the formula:



wherein

A is Cl or CF_3;

C is Cl or CF_3;

D is H or CH_3;

V is F or Cl;

X is a member selected from the group consisting of H, CH_3, COOH, and CO_2CH_3; and

Y is a member selected from the group consisting of H, CO_2H and CO_2CH_3;

or a pharmaceutically acceptable salt thereof.

51. (Previously Presented) The composition of claim 50, wherein V is Cl.

52. (Previously Presented) The composition of claim 50, wherein X and Y are each H.

53. (Previously Presented) The composition of claim 50, wherein A is Cl.

54. (Previously Presented) The composition of claim 50, wherein A is CF_3.

55. (Previously Presented) The composition of claim 50, wherein D is H.

56. (Previously Presented) The composition of claim 50, wherein A is Cl and D is H,

57. (Previously Presented) The composition of claim 50, wherein A is Cl; C is Cl; and V is Cl.

58. (Previously Presented) The composition of claim 50, wherein C is CF_3.

59. (Previously Presented) The composition of claim 50, wherein A is Cl; C is Cl; V is Cl, D is CH_3, and X and Y are each H.

60. (Previously Presented) The composition of claim 50, wherein A is Cl; C is Cl; V is Cl, D is H, and X and Y are each H.

61. (Previously Presented) A method for treating or preventing a metabolic disorder or an inflammatory condition, comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the formula:



wherein

A is Cl or CF_3;

C is Cl or CF_3;

D is H or CH_3;

V is F or Cl;

X is a member selected from the group consisting of H, CH_3, COOH, and CO_2CH_3; and

Y is a member selected from the group consisting of H, CO_2H and CO_2CH_3;

or a pharmaceutically acceptable salt thereof.

62. (Previously Presented) The method of claim 61, wherein A is Cl; C is Cl; D is H; V is Cl; and X and Y are each H.

63. (Previously Presented) The method of claim 61, wherein said subject is a human.

64. (Previously Presented) The method of claim 61, wherein said administering is oral.

65. (Previously Presented) The method of 61, wherein said administering is parenteral.

66. (Previously Presented) The method of claim 61, wherein said administering is topical.

67. (Previously Presented) The method of claim 61, wherein said metabolic disorder is selected from the group consisting of non-insulin dependent diabetes mellitus, obesity, hypercholesterolemia, hyperlipidemia, dyslipidemia, hypertriglylceridemia, hyperglycemia, insulin resistance and hyperinsulinemia.

68. (Previously Presented) The method of claim 61, wherein said inflammatory condition is selected from the group consisting of rheumatoid arthritis and atherosclerosis.

69. (Previously Presented) The method of claim 61, wherein said metabolic disorder or inflammatory condition is mediated by PPARγ.

70. (Previously Presented) The method of claim 61, wherein the metabolic disorder is non-insulin dependent diabetes mellitus.

71. (Currently Amended) A method for treating or preventing a condition or disorder mediated by PPARγ, comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the formula:



wherein

A is Cl or CF_3;

C is Cl or CF_3;

D is H or CH_3;

V is F or Cl;

X is a member selected from the group consisting of H, CH_3, COOH, and CO_2CH_3; and

Y is a member selected from the group consisting of H, CO_2H and CO_2CH_3;

or a pharmaceutically acceptable salt thereof, and wherein said condition or disorder is selected from the group consisting of non-insulin dependent diabetes mellitus, obesity, hypercholesterolemia, hyperlipidemia, dyslipidemia, hypertriglylceridemia, hyperglycemia, insulin resistance and hyperinsulinemia or is atherosclerosis.

72. (Previously Presented) The method of claim 71, wherein A is Cl; C is Cl; D is H; V is Cl; and X and Y are each H.

73. (Previously Presented) The method of claim 71, wherein said subject is a human.

74. (Previously Presented) The method of claim 71, wherein said administering is oral.

75. (Previously Presented) The method of claim 71, wherein said administering is parenteral.

76. (Previously Presented) The method of claim 71, wherein said administering is topical.

77. (Cancelled) The method of claim 71, wherein said condition or disorder is a metabolic disorder or an inflammatory condition.

78. (Cancelled) The method of claim 71, wherein said metabolic disorder is selected from the group consisting of non-insulin dependent diabetes mellitus, obesity, hypercholesterolemia, hyperlipidemia, dyslipidemia, hypertriglylceridemia, hyperglycemia, insulin resistance and hyperinsulinemia.

79. (Cancelled) The method of claim 71, wherein said inflammatory condition is selected from the group consisting of rheumatoid arthritis and atherosclerosis.

80. (Previously Presented) A method for modulating PPARγ, comprising contacting a cell with a compound having the formula:



wherein

A is Cl or CF_3;

C is Cl or CF_3;

D is H or CH_3;

V is F or Cl;

X is a member selected from the group consisting of H, CH_3, COOH, and CO_2CH_3; and

Y is a member selected from the group consisting of H, CO_2H and CO_2CH_3;

or a pharmaceutically acceptable salt thereof.

81. (Previously Presented) The method in accordance with claim 80, wherein A is Cl; C is Cl; D is H; V is Cl; and X and Y are each H.

82. (Previously Presented) The method of claim 80, wherein said compound is a PPARγ antagonist.

83. (Currently Amended) The method of Claim 80, wherein said compound is a PPARγ agonist.

84. (New) The method of Claim 61, wherein said metabolic disorder or inflammatory condition is treated.

85. (New) The method of Claim 71, wherein said disorder or condition is treated.